Mayor Sylvester Turner bikes the new Brays Bayou Greenway Bridge. Photo by Anthony Rathbun

In effort to make Houston more walkable and bike-friendly, city organizations have completed an important step in connectivity with the opening of a crucial new bridge.

Leaders from various city groups recently celebrated the ribbon cutting for the Brays Bayou Greenway Bridge, which will serve as an important connection between the University of Houston and the future home of the UH College of Medicine — as well as MacGregor Park.

The Brays Bayou Greenway Bridge runs along Martin Luther King Jr. Boulevard and the METRO Rail Purple Line. The pedestrian/bike bridge is an essential link in the 36.98-mile Brays Bayou Greenway.

Land acquisition, design, and construction of the Brays Bayou Greenway Bridge project cost $3.3 million. Engineering firm Halff Associates, along with SWA, designed the project. The Texas Department of Transportation led the construction effort and was provided funding through the Houston-Galveston Area Council. Altus was the general contractor. The University of Houston provided the easement for the bridge.

The new connector is part of the city's Bayou Greenways 2020, a public-private partnership between the Houston Parks Board, the City of Houston, the Houston Parks and Recreation Department, and the Harris County Flood Control District.

Bayou Greenways 2020 will transform 3,000 acres of underutilized land along nine major waterways and create a 150-mile network of connected parks and trails along Houston's major waterways, according to a release. In 2012, Houston voters overwhelmingly approved a bond proposal that set aside $100 million for Bayou Greenways 2020.

Houston Parks Board is raising an additional $120 million and is managing acquisition, design and construction of the Bayou Greenways. More than $110 million has been raised to date, including a historic $50 million donation from the Kinder Foundation.

"The Brays Bayou Greenway Bridge is significant because it is an essential connector in the Brays Bayou Greenway trail system. In addition to benefiting the University of Houston, this bridge is also a new link for the Third Ward community," said Beth White, President and CEO of Houston Parks Board, in a statement. "Individuals and families can use the trails to commute to work, walk to school, or just for fun."

Also at the ribbon-cutting event, Houston BCycle celebrated its 100th bike share station located in MacGregor Park, which opened in October 2019. To date, the organization has 109 bike share stations across Houston.

"Bayou Greenways 2020 is about more than just recreation; it's about bringing Houstonians together," said Mayor Sylvester Turner, at the event. "Communities are strengthened through partnerships like this. Not only do we have a beautiful bridge connecting neighborhoods, like the Third Ward Complete Community, but we have a great way to explore the trails through BCycle's bike share stations."

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”